Skip to main content

Table 1 Association between baseline subject characteristics and HU: EU and Non-EU cohorts

From: Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study

Non-EU cohort EU cohort
Baseline characteristic C Baseline characteristic C
Age (years) 0.16 Age 0.34
Alcohol use (Yes) −0.19 Alcohol use (Yes) −1.03
Height (cm) 0.158* Height (cm) 0.247
Weight (kg) −0.115* Weight (kg) −0.385**
Country AU vs. US −4.359* Country BE vs. UK −9.088*
Country CA vs. US −0.570 Country NL vs. UK −2.997
Country NZ vs. US −1.056 Country SE vs. UK −3.684
Smoke (Yes) −5.204* Smoke (Yes) −8.712**
Prevalent vertebral fractures −0.638 Prevalent vertebral fractures −2.245**
Baseline femoral neck BMD (# of SDs < mean for females) −0.885 Baseline femoral neck BMD (# of SDs < mean for females) 2.192
Number of preexisting conditions −0.447*** Number of preexisting conditions −1.434***
Number of ONF −0.549 Number of ONF 0.751
Years postmenopausal −0.095 Years postmenopausal −0.305
Family history of osteoporosis (Yes) −1.004 Family history of osteoporosis (Yes) 4.332
History of hysterectomy (Yes) −0.008 History of hysterectomy (Yes) −4.723*
Married (Yes) −0.118 Married (Yes) 0.587
Years of education 0.347* Years of education 0.370
Baseline LS BMD (# of SDs < mean for females) 0.472 Baseline LS BMD (# of SDs < mean for females) −0.209
Variance explained 0.14 Variance explained 0.20
  1. Abbreviations: AU Australia, BMD Bone mineral density (score), BE Belgium, C Regression coefficient, CA Canada, EU European Union, LS Lumbar spine, NL Netherlands, Non-EU Non-European Union, NZ New Zealand, ONF Osteoporotic non-vertebral fractures, SD Standard deviation, SE Sweden, UK Great Britain, US United States.
  2. *p < 0.05, **p < 0.001, ***p < 0.0001.